Aurobindo Pharma Ltd’s consolidated net profit increased 7 per cent at Rs 432 crore in the first quarter ended June 30, 2015 compared to Rs 404 crore in the corresponding quarter of the previous year.
The revenue of the company increased 5 per cent at Rs 3,320 crore compared to Rs 3,162 crore in the year-ago period.
“We are pleased to initiate the year with broad based growth across most business verticals. We continue on our efforts towards higher degree of differentiation including specialty generics and active pharmaceutical ingredients,’’ N Govindarajan, its Managing Director said in a release.
The earnings per share stood at Rs 14.81 (Rs 14.25). Aurobindo had received eight and four approvals for various drugs from the USA and Canada respectively during the quarter under review.
Aurobindo’s scrip lost 2.32 per cent on the Bombay Stock Exchange on Wednesday to end at Rs 744.20